MGC Pharma's pioneering cannabis-based treatment for refractory epilepsy now available to patients in the United Kingdom
LONDON, May 31, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE:MXC.LN), (AMEX:MXC), (OTC:MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received by its first patients in the United Kingdom.
Read more at prnewswire.com